Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83


USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics.

Russell SM, Lechner MG, Gong L, Megiel C, Liebertz DJ, Masood R, Correa AJ, Han J, Puri RK, Sinha UK, Epstein AL.

Oral Oncol. 2011 Sep;47(9):810-7. doi: 10.1016/j.oraloncology.2011.05.015. Epub 2011 Jun 29.


Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1.

Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, Puri RK, Correa AJ, Epstein AL.

Head Neck Oncol. 2010 Feb 22;2:5. doi: 10.1186/1758-3284-2-5.


Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.

Younis RH, Han KL, Webb TJ.

J Immunol. 2016 Feb 1;196(3):1419-29. doi: 10.4049/jimmunol.1501293. Epub 2016 Jan 6.


Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.

Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB, Whiteside TL.

Cancer Res. 1989 Sep 15;49(18):5167-75.


Opposing function of MYBBP1A in proliferation and migration of head and neck squamous cell carcinoma cells.

Acuña Sanhueza GA, Faller L, George B, Koffler J, Misetic V, Flechtenmacher C, Dyckhoff G, Plinkert PP, Angel P, Simon C, Hess J.

BMC Cancer. 2012 Feb 17;12:72. doi: 10.1186/1471-2407-12-72.


Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Sepiashvili L, Hui A, Ignatchenko V, Shi W, Su S, Xu W, Huang SH, O'Sullivan B, Waldron J, Irish JC, Perez-Ordonez B, Liu FF, Kislinger T.

Mol Cell Proteomics. 2012 Nov;11(11):1404-15. doi: 10.1074/mcp.M112.020933. Epub 2012 Aug 23.


Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Johnson SD, Levingston C, Young MR.

Anticancer Res. 2016 Jul;36(7):3261-70.


Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.

Harris M, Wang XG, Jiang Z, Goldberg GL, Casadevall A, Dadachova E.

Head Neck Oncol. 2011 Feb 12;3(1):9. doi: 10.1186/1758-3284-3-9.


Identification of guanine nucleotide-binding protein γ-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling.

Demokan S, Chuang AY, Chang X, Khan T, Smith IM, Pattani KM, Dasgupta S, Begum S, Khan Z, Liegeois NJ, Westra WH, Sidransky D, Koch W, Califano JA.

Int J Oncol. 2013 Apr;42(4):1427-36. doi: 10.3892/ijo.2013.1808. Epub 2013 Feb 6.


Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.

Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C.

Clin Cancer Res. 1999 Jun;5(6):1369-79.


Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes.

Kacani L, Wurm M, Schennach H, Braun I, Andrle J, Sprinzl GM.

Oral Oncol. 2003 Oct;39(7):672-9.


14-3-3ζ regulates immune response through Stat3 signaling in oral squamous cell carcinoma.

Han X, Han Y, Jiao H, Jie Y.

Version 2. Mol Cells. 2015 [revised 2015 Mar 10];38(2):112-21. doi: 10.14348/molcells.2015.2101. Epub 2014 Dec 30.


Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd.

Surgery. 2012 Sep;152(3):431-40. doi: 10.1016/j.surg.2012.05.035. Epub 2012 Jul 6.


Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma.

Marcus B, Arenberg D, Lee J, Kleer C, Chepeha DB, Schmalbach CE, Islam M, Paul S, Pan Q, Hanash S, Kuick R, Merajver SD, Teknos TN.

Cancer. 2004 Dec 15;101(12):2779-87.


Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.

Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM.

J Transl Med. 2013 Aug 27;11:198. doi: 10.1186/1479-5876-11-198. Erratum in: J Transl Med. 2014;12:67. Lai, Stephen Y [added].


Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome.

de Koning PJ, Bovenschen N, Leusink FK, Broekhuizen R, Quadir R, van Gemert JT, Hordijk GJ, Chang WS, van der Tweel I, Tilanus MG, Kummer JA.

Int J Cancer. 2009 Oct 1;125(7):1542-50. doi: 10.1002/ijc.24507.


Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.

Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM.

Cancer Res. 2004 Jan 1;64(1):55-63.

Supplemental Content

Support Center